{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:53:28Z","timestamp":1792428808675,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011240","name":"Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Foundation","doi-asserted-by":"publisher","award":["AWD011295, 2018 Study of Neuromodulation funded by Medtronic"],"award-info":[{"award-number":["AWD011295, 2018 Study of Neuromodulation funded by Medtronic"]}],"id":[{"id":"10.13039\/100011240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Posterior tibial nerve stimulation (PTNS) is a promising treatment for lower urinary tract symptoms (LUTS) in patients with MS. However, long term data focusing on PTNS impact on health-related quality of life (HRQOL), bowel and bladder symptoms are lacking. This paper describes a study protocol that examines the extended efficacy of PTNS on MS related bladder and bowel symptoms and resulting HRQOL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/Design<\/jats:title>\n                <jats:p>This is a single-centered, prospective, longitudinal, observational cohort study of patients with MS who suffer from LUTS and are refractory to two prior treatment modalities. Participants who have elected to pursue PTNS therapy for LUTS will be eligible. The primary outcome is the median number of urinary frequency and incontinence episodes on a 3-day voiding diary at 3, 12 and 24\u2009months compared to baseline. Secondary outcome measures will include change in total AUA-SS, M-ISI, NBSS, SF-12, SSS and BCS scores from baseline The Expanded Disability Status Scale and magnetic resonance imaging will be evaluated at baseline and annually throughout the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This research protocol aims to expand on the existing literature regarding outcomes of PTNS in MS. Specifically, it will provide long term follow-up data on bladder, bowel, sexual and HRQOL outcomes. The completion of this study will provide longitudinal efficacy data of the impact of PTNS in MS patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04063852\">NCT04063852<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-020-00629-y","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T11:03:40Z","timestamp":1590577420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: design and methods"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6977-5280","authenticated-orcid":false,"given":"Giulia I.","family":"Lane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paholo","family":"Barboglio-Romo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Quentin","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne P.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Stoffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"10","key":"629_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340.","journal-title":"Neurology."},{"key":"629_CR2","unstructured":"Types of MS. National Multiple Sclerosis Society. Available from: https:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS. Cited 2019 May 20."},{"issue":"9313","key":"629_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221\u201331.","journal-title":"Lancet."},{"issue":"9","key":"629_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/jnnp.2010.208173","volume":"81","author":"M Koch","year":"2010","unstructured":"Koch M, Kingwell E, Rieckmann P, Tremlett H, UBC MS. Clinic neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1039\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"629_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology."},{"issue":"1","key":"629_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7224\/1537-2073.2013-040","volume":"17","author":"KM Khalaf","year":"2015","unstructured":"Khalaf KM, Coyne KS, Globe DR, Armstrong EP, Malone DC, Burks J. Lower urinary tract symptom prevalence and management among patients with multiple sclerosis. Int J MS Care. 2015;17(1):14\u201325.","journal-title":"Int J MS Care"},{"issue":"4","key":"629_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/ene.12370","volume":"21","author":"M Di Filippo","year":"2014","unstructured":"Di Filippo M, Proietti S, Gaetani L, Gubbiotti M, Di Gregorio M, Eusebi P, et al. Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. Eur J Neurol. 2014;21(4):648\u201353.","journal-title":"Eur J Neurol"},{"issue":"4","key":"629_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ucl.2010.06.003","volume":"37","author":"JT Stoffel","year":"2010","unstructured":"Stoffel JT. Contemporary management of the neurogenic bladder for multiple sclerosis patients. Urol Clin North Am. 2010;37(4):547\u201357.","journal-title":"Urol Clin North Am"},{"key":"629_CR9","unstructured":"Overactive Bladder (OAB) Guideline - American Urological Association. Available from: https:\/\/www.auanet.org\/guidelines\/overactive-bladder-(oab)-guideline. Cited 2019 May 15."},{"issue":"6 Suppl","key":"629_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","volume":"188","author":"EA Gormley","year":"2012","unstructured":"Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline. J Urol. 2012;188(6 Suppl):2455\u201363.","journal-title":"J Urol"},{"issue":"4","key":"629_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.juro.2018.04.068","volume":"200","author":"E Dray","year":"2018","unstructured":"Dray E, Cameron AP, Clemens JQ, Qin Y, Covalschi D, Stoffel J. Does post-void residual volume predict worsening urological symptoms in patients with multiple sclerosis? J Urol. 2018;200(4):868\u201374.","journal-title":"J Urol"},{"issue":"6","key":"629_CR12","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, Sievert K-D, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131\u20139.","journal-title":"J Urol"},{"issue":"7","key":"629_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/01.ogx.0000484817.63665.df","volume":"71","author":"F Puccini","year":"2016","unstructured":"Puccini F, Bhide A, Elneil S, Digesu GA. Sacral Neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis. Obstet Gynecol Surv. 2016;71(7):401.","journal-title":"Obstet Gynecol Surv"},{"key":"629_CR14","volume-title":"Medtronic","author":"Information for Prescribers","year":"2018","unstructured":"Information for Prescribers. Medtronic; 2018. Available from: http:\/\/manuals.medtronic.com\/content\/dam\/emanuals\/neuro\/M976705A_a_001_view.pdf."},{"issue":"4","key":"629_CR15","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.juro.2009.12.036","volume":"183","author":"KM Peters","year":"2010","unstructured":"Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438\u201343.","journal-title":"J Urol"},{"issue":"2","key":"629_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2006.07.024","volume":"51","author":"MV Fjorback","year":"2007","unstructured":"Fjorback MV, van Rey FS, van der Pal F, Rijkhoff NJM, Petersen T, Heesakkers JP. Acute urodynamic effects of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with MS. Eur Urol. 2007;51(2):464\u201370 discussion 471\u20132.","journal-title":"Eur Urol"},{"issue":"4","key":"629_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.urology.2007.11.135","volume":"71","author":"SC Kabay","year":"2008","unstructured":"Kabay SC, Yucel M, Kabay S. Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. Urology. 2008;71(4):641\u20135.","journal-title":"Urology."},{"issue":"8","key":"629_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/nau.20733","volume":"28","author":"S Kabay","year":"2009","unstructured":"Kabay S, Kabay SC, Yucel M, Ozden H, Yilmaz Z, Aras O, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964\u20138.","journal-title":"Neurourol Urodyn"},{"issue":"12","key":"629_CR19","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1177\/1352458511414040","volume":"17","author":"C Gobbi","year":"2011","unstructured":"Gobbi C, Digesu GA, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. Mult Scler. 2011;17(12):1514\u20139.","journal-title":"Mult Scler"},{"issue":"3","key":"629_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.juro.2013.09.036","volume":"191","author":"C Zecca","year":"2014","unstructured":"Zecca C, Digesu GA, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol. 2014;191(3):697\u2013702.","journal-title":"J Urol"},{"issue":"3","key":"629_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/ene.12339","volume":"21","author":"C Zecca","year":"2014","unstructured":"Zecca C, Digesu GA, Robshaw P, Puccini F, Khullar V, Tubaro A, et al. Motor and sensory responses after percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract symptoms treated in daily practice. Eur J Neurol. 2014;21(3):506\u201311.","journal-title":"Eur J Neurol"},{"issue":"1","key":"629_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/nau.22868","volume":"36","author":"S Canbaz Kabay","year":"2017","unstructured":"Canbaz Kabay S, Kabay S, Mestan E, Cetiner M, Ayas S, Sevim M, et al. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2017;36(1):104\u201310.","journal-title":"Neurourol Urodyn"},{"key":"629_CR23","doi-asserted-by":"crossref","unstructured":"Cox L, Cameron AP, Wittman D, Papin JE, Stoffel JT. Analysis Of Urinary Symptoms And Urodynamic Findings In Multiple Sclerosis Patients By Gender And Disease Subtype. J Neurol Neurobiol. 2015; 1(2). Available from: https:\/\/www.researchgate.net\/publication\/276961511_Analysis_Of_Urinary_Symptoms_And_Urodynamic_Findings_In_Multiple_Sclerosis_Patients_By_Gender_And_Disease_Subtype. Cited 2019 Apr 8.","DOI":"10.16966\/2379-7150.105"},{"issue":"7","key":"629_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ner.12764","volume":"21","author":"S Sanagapalli","year":"2018","unstructured":"Sanagapalli S, Neilan L, Lo JYT, Anandan L, Liwanag J, Raeburn A, et al. Efficacy of percutaneous posterior Tibial nerve stimulation for the Management of Fecal Incontinence in multiple sclerosis: a pilot study: PTNS for fecal incontinence in multiple sclerosis. Neuromodulation. 2018;21(7):682\u20137.","journal-title":"Neuromodulation"},{"issue":"2","key":"629_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"2","key":"629_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2015.07.071","volume":"69","author":"J Groen","year":"2016","unstructured":"Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, et al. Summary of European Association of Urology (EAU) guidelines on Neuro-urology. Eur Urol. 2016;69(2):324\u201333.","journal-title":"Eur Urol"},{"issue":"3","key":"629_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/nau.20994","volume":"30","author":"E Bright","year":"2011","unstructured":"Bright E, Drake MJ, Abrams P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn. 2011;30(3):348\u201352.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"629_CR28","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr, O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549\u201357 discussion 1564.","journal-title":"J Urol"},{"issue":"2","key":"629_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/nau.22953","volume":"36","author":"SJ Weissbart","year":"2017","unstructured":"Weissbart SJ, Pechersky D, Malykhina A, Bavaria T, Parrillo L, Arya LA, et al. The impact of pontine disease on lower urinary tract symptoms in patients with multiple sclerosis. Neurourol Urodyn. 2017;36(2):453\u20136.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"629_CR30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/nau.22468","volume":"33","author":"AM Suskind","year":"2014","unstructured":"Suskind AM, Dunn RL, Morgan DM, DeLancey JOL, McGuire EJ, Wei JT. The Michigan incontinence symptom index (M-ISI): a clinical measure for type, severity, and bother related to urinary incontinence. Neurourol Urodyn. 2014;33(7):1128\u201334.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"629_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.juro.2014.01.027","volume":"192","author":"B Welk","year":"2014","unstructured":"Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014;192(2):452\u20137.","journal-title":"J Urol"},{"issue":"6","key":"629_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1191\/1352458503ms971oa","volume":"9","author":"RA Marrie","year":"2003","unstructured":"Marrie RA, Miller DM, Chelune GJ, Cohen JA. Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. Mult Scler. 2003;9(6):621\u20136.","journal-title":"Mult Scler"},{"key":"629_CR33","unstructured":"Guidebook - MSQLI Manual and Forms (.pdf). Available from: https:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Brochures\/MSQLI_-A-User-s-Manual.pdf."},{"issue":"3","key":"629_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333.","journal-title":"Med Care"},{"issue":"10","key":"629_CR35","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/00005650-200010000-00006","volume":"38","author":"MW Nortvedt","year":"2000","unstructured":"Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 2000;38(10):1022\u20138.","journal-title":"Med Care"},{"issue":"11","key":"629_CR36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology."},{"key":"629_CR37","unstructured":"Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 3 day voiding Diary. SUFU 3 day voiding diary. Available from: https:\/\/sufuorg.com\/docs\/guidelines\/sufu-voiding-diary-faq.aspx. Cited 2019 Apr 5."},{"issue":"3","key":"629_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/nau.20958","volume":"30","author":"M de S\u00e8ze","year":"2011","unstructured":"de S\u00e8ze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306\u201311.","journal-title":"Neurourol Urodyn"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00629-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-020-00629-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00629-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:19:38Z","timestamp":1622071178000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00629-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00629-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Review Board (Ethics approval) has been obtained for this study from the University of Michigan: HUM00153287. Participants will provide written informed consent prior to initiating in the study protocol. Amendments to IRB will be declared at final publication of study and on the trial registry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GL: no competing interests. YMD has served as a consultant and\/or received grant support from: Acorda, Bayer Pharmaceutical, Biogen Idec, EMD Serono, Genzyme, Novartis, Questor, Chugai Pharmaceuticals, and Teva Neuroscience. Dr. Mao-Draayer is currently supported by grants from the NIH NIAID Autoimmune Center of Excellence: UM1-AI110557; NIH NINDS R01-NS080821, PCORI, Chugai, Novartis and Genzyme. PBR: no competing interests. QC: no competing interests. PG: no competing interests. RD: no competing interests. YQ: no competing interests. AC: reports personal fees from Wellspect, grants from Medtronic, outside of the submitted work. JS is supported by grants from the Department of Defense; received grant support from Ipsen, Uroplasty.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}